ASCO 2019 and the future of oncology/ Oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial mike.smith@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share X ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – phase I data generates hope for the future mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share X ASCO 2019 – phase I data generates hope for the future https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
ASCO 2019 Live coverage/ Oncology/ Views & Analysis/ Views and analysis ASCO 2019 day five mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Exclusive live coverage from day five of the American Society of Clinical Oncology’s annual meeting in Chicago. • Share X ASCO 2019 day five https://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-five/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Enfortumab comes out fighting in bladder cancer mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) Share X ASCO 2019 – Enfortumab comes out fighting in bladder cancer https://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase Share X ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results https://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial mike.smith@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Share X ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Kantar reviews results from phase 3 POLO trial mike.smith@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based Share X ASCO 2019 – Kantar reviews results from phase 3 POLO trial https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-phase-3-polo-trial/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Kantar reviews multiple myeloma showdown mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen’s Darzalex and Share X ASCO 2019 – Kantar reviews multiple myeloma showdown https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-multiplemyeloma-data/
ASCO 2019 Live coverage/ Oncology/ Views & Analysis/ Views and analysis ASCO 2019 day four mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Exclusive live coverage from day four of the American Society of Clinical Oncology’s annual meeting in Chicago. • Share X ASCO 2019 day four https://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-four/
